Physician profile
Tiffany S Bennett
NPI 1134785769
$4,162.35
in general payments reported to CMS, 2019-2025
34 companies · $315 in 2025
The $315 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,204 · 2022: $1,015 · 2023: $990 · 2024: $638 · 2025: $315.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,844 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,843.93 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $719.06 | 2021-2024 | |
| Novo Nordisk INC | $697.54 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $651.63 | 2021-2024 | Arexvy, Trelegy Ellipta |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $249.77 | 2023-2025 | Caplyta |
| Amgen INC. | $178.05 | 2021-2025 | Otezla, Repatha, Krystexxa |
| Esperion Therapeutics, INC. | $164.29 | 2021-2024 | Nexlizet, Nexletol |
| Astellas Pharma US INC | $154.00 | 2024-2025 | Veozah |
| Lilly USA, LLC | $134.92 | 2021-2024 | Jardiance |
| Horizon Therapeutics Plc | $126.87 | 2022 | |
| Janssen Pharmaceuticals, INC | $115.43 | 2021-2022 | |
| Pfizer INC. | $101.85 | 2021-2023 | |
| Sanofi-Aventis U.S. LLC | $85.30 | 2021 | |
| Xeris Pharmaceuticals, INC. | $82.09 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $74.06 | 2021-2024 | Farxiga |
| Janssen Biotech, INC. | $69.60 | 2021-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $66.67 | 2021-2022 | |
| Radius Health, INC. | $53.71 | 2024 | Tymlos |
| Bayer Healthcare Pharmaceuticals INC. | $45.06 | 2023-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.86 | 2021-2024 | Jardiance |
| Abbott Laboratories | $43.80 | 2023-2024 | Freestyle Libre |
| Daiichi Sankyo INC. | $42.83 | 2021 | |
| Gilead Sciences, INC. | $30.10 | 2022-2025 | |
| Boston Scientific Corporation | $25.81 | 2024 | Wavewriter Alpha Prime 16 |
| Dexcom, INC. | $21.75 | 2023 | Dexcom G6 Transmitter |
| Lexicon Pharmaceuticals, INC. | $21.73 | 2023 | Inpefa |
| Mylan Specialty L.P. | $20.94 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.55 | 2021 | |
| Merck Sharp & Dohme LLC | $19.87 | 2024 | Keytruda |
| Amarin Pharma, INC. | $17.45 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $17.19 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $17.15 | 2021 | |
| Acacia Pharma INC | $16.47 | 2022 | |
| Exact Sciences Corporation | $16.06 | 2023 | Cologuard Collection Kit |
| Ibsa Pharma INC. | $15.89 | 2024 | Tirosint, Licart |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tiffany Bennett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.